Learn More
There is no standard second line therapy for relapsed oesophago-gastric (O-G) cancer. We recruited 29 eligible patients with relapsed O-G cancer who had progressed during or within 3 months of prior(More)
PURPOSE This preclinical and phase II study evaluated the efficacy and safety of the combination of cetuximab and erlotinib in metastatic colorectal cancer (mCRC). PATIENTS AND METHODS The activity(More)